Axonics® submits pma supplement to fda to further expand mri labeling

Irvine, calif.--(business wire)--axonics modulation technologies, inc. (nasdaq: axnx), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (snm) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (pma) supplement to the fda for the purpose of gaining detachable extremity coil magnetic resonance imaging (mri) conditional labeling for 1.5t and 3.0t mr scanners. the fda previously approved 1.5t
AXNX Ratings Summary
AXNX Quant Ranking